Related Experiment Video
Updated: Sep 8, 2025
Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility
Published on: April 13, 2017
Targeting KCNN4 channels modulates microglial activation and apoptosis in a PD-relevant inflammatory model
Hao-Yuan Hung1, I-Hsun Li2, Yung-Ni Lin3
1Department and Graduate Institute of Pharmacology, College of Pharmacy, National Defense Medical University, Taipei, Taiwan; Department of Pharmacy Practice, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
Pharmacological inhibition of KCNN4 channels with TRAM-34 reduces neuroinflammation and apoptosis in a Parkinson's disease mouse model. This approach preserves dopaminergic neurons and improves motor function, highlighting KCNN4 as a therapeutic target for Parkinson's disease.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Parkinson's disease (PD) involves chronic neuroinflammation and dopaminergic neurodegeneration.
- Microglial activation and apoptosis are key drivers of PD pathogenesis.
- The KCNN4 channel is a potential therapeutic target, but its role in PD is unclear.
Purpose of the Study:
- To investigate the effects of KCNN4 inhibition using TRAM-34 on neuroinflammation and apoptosis in an LPS-induced PD mouse model.
- To evaluate the therapeutic potential of targeting KCNN4 for PD treatment.
Main Methods:
- Utilized an LPS-induced mouse model of Parkinson's disease.
- Administered TRAM-34 (KCNN4 inhibitor) and assessed inflammatory markers (COX-2, TLR4, IL-1β, Iba1).
- Evaluated dopaminergic neuron preservation (tyrosine hydroxylase), apoptosis markers (p53, cytochrome c, PARP-1), and dopamine transporter levels ([¹⁸F]FE-PE2I PET).
- Conducted behavioral assessments (rotarod test) and in vitro microglial studies.
Main Results:
- TRAM-34 suppressed microglial activation and reduced key inflammatory mediators.
- Treatment preserved dopaminergic neurons and attenuated apoptotic signaling pathways.
- PET imaging showed partial restoration of striatal DAT, and behavioral tests indicated improved motor function.
Conclusions:
- KCNN4 inhibition with TRAM-34 effectively modulates microglial activation, neuroinflammation, and apoptosis in a PD model.
- TRAM-34 demonstrates neuroprotective effects, preserving dopaminergic neurons and improving motor deficits.
- Targeting KCNN4 channels offers a promising therapeutic strategy for mitigating neurodegeneration in Parkinson's disease.
